Showing results (41-50 of 191) with videos related to
Sort By:
Pageof 20
Thoracic Cancer|April 8, 2021
Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesotheliomaKageaki Watanabe, Yusuke Okuma, Shoko Kawai, et al.Clinical Journal of Gastroenterology|July 21, 2015
A case of polymyositis in a chronic hepatitis C patient treated with peg-interferon-alpha 2b and ribavirin therapyYusuke Okuma, Kiminori Kimura, Shunichi Saeki, et al.Journal of Cancer Research and Clinical Oncology|May 29, 2020
Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancerTaiki Hakozaki, Yukio Hosomi, Rui Kitadai, et al.Journal of Cancer Research and Clinical Oncology|August 23, 2014
Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapyYusuke Okuma, Makoto Saito, Yukio Hosomi, et al.Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancerYusuke Okuma, Yukio Hosomi, Yoshiro Nakahara, et al.Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 7, 2016
Characteristics of laryngeal symptoms induced in patients with allergic rhinitis in an environmental challenge chamberTakeshi Suzuki, Yoshitaka Okamoto, Syuji Yonekura, et al.Journal of Thoracic Disease|December 23, 2017
Chemoradiotherapy for unresectable cases of thymic epithelial tumors: a retrospective studyJumpei Kashima, Yusuke Okuma, Hiroto Murata, et al.Lung Cancer (Amsterdam, Netherlands)|June 9, 2026
Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in JapanYuji Uehara, Masachika Ikegami, Shinji Kohsaka, et al.Clinical Lung Cancer|December 4, 2014
Response to cytotoxic chemotherapy in patients previously treated with palliative-intent chemotherapy for advanced thymic carcinomaYusuke Okuma, Yukio Hosomi, Satoshi Takahashi, et al.BMC Cancer|February 27, 2016
Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinomaYusuke Okuma, Yukio Hosomi, Shingo Miyamoto, et al.Pageof 20